Using the agreed starting and stopping criteria adalimumab can continue to be made available within NHS Wales to treat paediatric patients (aged ≥ 2 to ≤ 18 years) with severe refractory non-infectious intermediate, posterior and pan- uveitis.

Adalimumab should be initiated in specialist centres for this indication.

Adalimumab is not licensed to treat this indication and is therefore ‘off-label’. Each provider organisation must ensure all internal governance arrangements are completed before this medicine is prescribed.

The risks and benefits of the off-label use of adalimumab for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

This advice will be reviewed after 2 years or earlier if new evidence becomes available.